DaltonTx said it expanded its AI engine for antibody discovery and management, including adding upstream process support such as assays and experimental outcomes. The company positions the system as a modality-independent decision engine that combines AI-generated predictions with project data and prior experimental knowledge to recommend what to progress next. DaltonTx’s claims include rapid structural prediction and large-scale sequence handling, alongside a chat interface aimed at helping scientists troubleshoot antibody selection decisions. The company also pointed to academic collaboration with the University of Oxford and earlier partnership activity with Bonito Biosciences for AI-driven oligo therapies. The update highlights continued momentum toward AI-first discovery workflows that treat experimental data as a continuously fed decision loop rather than static training inputs.